InSilico Medicine Invests $105 Million in Wealth Management Products

MT Newswires Live04-30

InSilico Medicine (HKG:3696) invested $105 million in wealth management products offered by CMB International and JPMorgan, according to a Hong Kong bourse filing Thursday.

The AI-driven drug discovery firm invested $50 million in a money market fund managed by CMB International Asset Management with an expected 3.99% annualized rate of return; $50 million in a variable net asset value money market fund by JPMorgan Asset Management with an expected 3.85% annualized rate of return; and a further $5 million in a dual-currency deposit issued by JPMorgan Chase Bank with an expected 4.68% rate of return.

The subscriptions were made with the view of "enhancing returns on surplus cash," the firm said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment